How has been the historical performance of Ajanta Pharma?

Jul 03 2025 10:32 PM IST

Share Via

Ajanta Pharma has demonstrated consistent financial growth, with net sales increasing from INR 2,055.37 crore in March 2019 to INR 4,648.10 crore in March 2025, alongside significant rises in operating profit and net profit. By March 2025, the net profit reached INR 920.39 crore, with a profit after tax margin of 19.8%.

Answer:

Ajanta Pharma has shown a consistent growth trajectory in its financial performance over the years, with net sales increasing from INR 2,055.37 crore in March 2019 to INR 4,648.10 crore in March 2025. The total operating income has mirrored this growth, rising from INR 2,055.37 crore in March 2019 to INR 4,648.10 crore in March 2025. The operating profit (PBDIT) has also seen a significant increase, reaching INR 1,354.00 crore in March 2025, up from INR 587.51 crore in March 2019. Profit before tax has improved from INR 514.27 crore in March 2019 to INR 1,189.16 crore in March 2025, while the net profit has grown from INR 386.97 crore to INR 920.39 crore in the same period. Earnings per share (EPS) have fluctuated, peaking at INR 75.20 in March 2021 before settling at INR 72.84 in March 2025. The company has maintained a healthy profit after tax margin, which was 19.8% in March 2025, reflecting its operational efficiency.

Breakdown:
Ajanta Pharma's financial performance has demonstrated robust growth over the years, with net sales climbing steadily from INR 2,055.37 crore in March 2019 to INR 4,648.10 crore in March 2025. This upward trend is complemented by a rise in total operating income, which reached INR 4,648.10 crore in March 2025. The operating profit (PBDIT) has also shown significant improvement, increasing from INR 587.51 crore in March 2019 to INR 1,354.00 crore in March 2025, indicating enhanced operational efficiency. Profit before tax has similarly risen, from INR 514.27 crore to INR 1,189.16 crore over the same period. The net profit has followed suit, growing from INR 386.97 crore in March 2019 to INR 920.39 crore in March 2025, showcasing the company's ability to convert revenue into profit effectively. Despite fluctuations, the earnings per share reached INR 72.84 in March 2025, reflecting the company's strong financial health and profitability. The profit after tax margin of 19.8% in March 2025 further underscores Ajanta Pharma's operational success.

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)

MOJO SCORE